Company intelligence / Profile preview

PulseCath

Netherlands

Ownership: Private
Development stage: Other

Overview

PulseCath has commercialized the iVAC 2L, a percutaneous left ventricular assist device (LVAD) for short-term mechanical circulatory support, and achieved MDR CE Certification in Europe. Early clinical use demonstrates successful hemodynamic support in high-risk PCI and cardiogenic shock, with improved accessibility due to simplified use and cost advantages. Pipeline also includes next generation pulsatile ECMO and RVAD/LVAD systems in development.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Huadong Medicine (Greater China commercialization partnership)[6]

Beyond the preview

Go deeper on PulseCath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PulseCath.

Explore the full profile